A Phase 1 Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Cedar Pollinosis When Administered as Intramuscular (IM) Vaccination and Intradermal (ID) Vaccination
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2016
At a glance
- Drugs ASP 4070 (Primary) ; ASP 4070 (Primary)
- Indications Allergic rhinitis; Tree pollen hypersensitivity
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 14 Sep 2016 Status changed from active, no longer recruiting to completed.
- 17 Aug 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to active, no longer recruiting.
- 17 Jun 2015 New trial record